Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 3/20 | 0.51 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.50 |
| ▸ | MET | P08581 | 8/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL210846 | 0.89 | HDAC1 (0.61) | ABL1PRMT3CYP3A4TP53RXFP1 | |
| SCHEMBL1064126 | 0.79 | HDAC1 (0.71) | CYP3A4TP53RXFP1HDAC1POLB | |
| SCHEMBL211323 | 0.74 | HDAC1 (0.85) | CYP3A4TP53RXFP1HDAC1MAPT | |
| SCHEMBL5476417 | 0.70 | PRMT3 (0.56) | PRMT3TP53MAPTSMN1; SMN2MEN1 | |
| SCHEMBL612904 | 0.70 | MET (0.64) | ABL1METCYP3A4POLBMAPT | |
| SCHEMBL613934 | 0.70 | ABL1 (0.69) | ABL1METCYP3A4POLBMAPT | |
| SCHEMBL543789 | 0.70 | ABL1 (0.69) | ABL1METCYP3A4POLBMAPT | |
| SCHEMBL30416740 | 0.69 | LMNA (0.73) | MAPTSMN1; SMN2LMNA | |
| SCHEMBL5741437 | 0.69 | MAPK1 (0.59) | POLBMAPTSMN1; SMN2MEN1NPC1 | |
| SCHEMBL2802346 | 0.69 | MET (0.87) | ABL1METCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7253204-B2 | Antiproliferative agents | METHYLGENE INC. (CA) | 2007-08-07 | — | — | US | disclosed |
| US-20050245518-A1 | Antiproliferative agents | METHYLGENE, INC. | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245518-A1 | Antiproliferative agents | HDAC1, HDAC11, HDAC5 | ABL1 1122/4885PRMT3 659/4885MET 1970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.